JG Kim, LL Baggio, DP Bridon, JP Castaigne, MF … - Diabetes, 2003 - Am Diabetes Assoc The rapid degradation of native glucagon-like peptide 1 (GLP-1) by dipeptidyl peptidase-IV (DPP-IV)
has fostered new approaches for generation of degradation-resistant GLP-1 analogues. We examined the
biological activity of CJC-1131, a ... Cited by 127 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org LL Baggio, Q Huang, TJ Brown, DJ Drucker - Diabetes, 2004 - Am Diabetes Assoc Peptide hormones exert unique actions via specific G protein–coupled receptors; however, the
therapeutic potential of regulatory peptides is frequently compromised by rapid enzymatic
inactivation and clearance from the ... Cited by 96 - Related articles - BL Direct - All 11 versions
RI Vivo - Diabetes, 2003 - Am Diabetes Assoc Page 1. Development and Characterization of a Glucagon-Like Peptide 1-Albumin Conjugate The Ability
to Activate the Glucagon-Like Peptide 1 Receptor In Vivo Jung-Guk Kim, 1 Laurie L. Baggio, 1
Dominique P. Bridon, 2 Jean-Paul Castaigne, 2 Martin F. Robitaille, 2 ... Cited by 1 - Related articles - All 5 versions
- ►diabetesjournals.org B Elbrønd, G Jakobsen, S Larsen, H Agersø, LB … - Diabetes Care, 2002 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In a double-blind, randomized dose, escalation, placebo-controlled
study, healthy male subjects were enrolled at eight consecutive dose levels (1.25, 2.5, 5.0, 10.0,
12.5, 15.0, 17.5, and 20.0 μg/kg) ... Cited by 103 - Related articles - BL Direct - All 6 versions
- ►physiology.org B Rolin, MO Larsen, CF Gotfredsen, CF … - American Journal of …, 2002 - Am Physiological Soc NN2211 is a long-acting, metabolically stable glucagon-like peptide-1 (GLP-1) derivative designed
for once daily administration in humans. NN2211 dose dependently reduced the glycemic levels in
ob/ob mice, with antihyperglycemic ... Cited by 130 - Related articles - BL Direct - All 4 versions
CB Juhl, M Hollingdal, J Sturis, G Jakobsen, H Agersø, … - Diabetes, 2002 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) is a potent glucose-lowering agent of potential interest for the
treatment of type 2 diabetes. To evaluate actions of NN2211, a long-acting GLP-1 derivative, we
examined 11 patients with type 2 ... Cited by 175 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org S Madsbad, O Schmitz, J Ranstam, G Jakobsen, … - Diabetes Care, 2004 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A double-blind, randomized, parallel-group, placebo-controlled trial
with an open-label comparator arm was conducted among 193 outpatients with type 2 diabetes. The mean
age was 56.6 years and the mean HbA ... Cited by 170 - Related articles - BL Direct - All 6 versions
LB Knudsen, PF Nielsen, PO Huusfeldt, NL Johansen, … - J. Med. Chem, 2000 - pubs.acs.org A series of very potent derivatives of the 30-amino acid peptide hormone glucagon-like peptide-1
(GLP-1) is described. The compounds were all derivatized with fatty acids in order to protract their
action by facilitating binding to ... Cited by 136 - Related articles - All 5 versions
Y Li, T Hansotia, B Yusta, F Ris, PA Halban, DJ … - Journal of Biological …, 2003 - ASBMB Glucagon-like peptide-1 (GLP-1) stimulates insulin secretion and augments β cell mass via
activation of β cell proliferation and islet neogenesis. We examined whether GLP-1 receptor
signaling modifies the cellular ... Cited by 254 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org KB Degn, CB Juhl, J Sturis, G Jakobsen, B Brock, V … - Diabetes, 2004 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) is potentially a very attractive agent for treating type 2 diabetes.
We explored the effect of short-term (1 week) treatment with a GLP-1 derivative, liraglutide
(NN2211), on 24-h dynamics in ... Cited by 170 - Related articles - BL Direct - All 8 versions
